TRIDM-2
Description
- Triple-drug formula for improved blood sugar control in Type 2 Diabetes
- Glimepiride (2 mg) promotes insulin secretion for postprandial control
- Metformin (500 mg) lowers liver glucose production and improves insulin sensitivity
- Voglibose (0.2 mg) delays carbohydrate absorption to control post-meal sugar spikes
- Helps manage both fasting and postprandial glucose levels
- Useful for patients needing a stronger dose of Glimepiride
- To be taken with meals for optimal effectiveness and reduced GI side effects
- Requires monitoring and guidance from a healthcare provider
Composition
GLIMIPRIDE-2 MG, VOGLOBOSE- 0.2 MG, METFORMINE-500 MG
Benefits
TRI-DM-2/500 offers a multi-targeted approach to diabetes management, making it especially beneficial for patients with uncontrolled or moderately advanced Type 2 Diabetes. Glimepiride ensures improved insulin output, Metformin enhances insulin action and reduces glucose production, and Voglibose minimizes glucose spikes after meals. This results in improved overall glycemic control, better HbA1c outcomes, and reduced risk of long-term diabetes complications when used along with dietary control and regular exercise.
Introduction
TRI-DM-2/500 is a triple-combination oral anti-diabetic tablet formulated to provide comprehensive glycemic control in patients with Type 2 Diabetes Mellitus. It contains Glimepiride (2 mg), which stimulates pancreatic insulin secretion; Metformin (500 mg), which reduces hepatic glucose production and improves insulin sensitivity; and Voglibose (0.2 mg), an alpha-glucosidase inhibitor that slows carbohydrate absorption in the intestines. This well-balanced combination helps in managing both fasting and postprandial blood glucose levels effectively.
